Therapeutic products: Regulating drugs and medical devices

International Handbook on Regulating Nanotechnologies

Volumn , Issue , 2010, Pages 291-320

  Gaspar, Rogério Sá ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84881937432     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (116)

1. Alexis, F., E. Pridgen, L.K. Molnar and O.C. Farokhzad (2008), 'Factors affecting the clearance and biodistribution of polymeric nanoparticles', Molecular Pharmaceutics, 5(4), 505-15.
2. Ballot, S., N. Noiret, F. Hindré, B. Denizot, E. Garin, H. Rajerison and J.P. Benoit (2006), '99mTc/188Re-labelled lipid nanocapsules as promising radiotracers for imaging and therapy: formulation and biodistribution', European Journal Nuclear Medicine Molecular Imaging, 33(5), 602-7.
3. Bawarski, W.E., E. Chidlowsky, D.J. Bharali and S.A. Mousa (2008), 'Emerging nanopharmaceuticals', Nanomedicine, 4(4), 273-82.
4. Bissett, D., J. Cassidy, J.S. de Bono, F. Muirhead, M. Main, L. Robson, D. Fraier, M.L. Magnè, C. Pellizzoni, M.G. Porro, R. Spinelli, W. Speed and C. Twelves (2004), 'Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)', British Journal of Cancer, 91, 50-55.
5. Brgles, M., B. Halassy, J. Tomasić, M. Santak, D. Forcić, M. Barut and A. Strancar (2007), 'Determination of DNA entrapment into liposomes using monolithic columns', Journal of Chromatography A, 1144(1), 150-54.
6. Campbell, R.B., B. Ying, G.M. Kuesters and R. Hemphill (2009), 'Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics', Journal of Pharmaceutical Sciences, 98(2), 411-29.
7. Cedervall, T., I. Lynch, S. Lindman, T. Berggård, E. Thulin, H. Nilsson, A. Kenneth, K.A. Dawson and S. Linse (2007), 'Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles', Proceedings National Academy Sciences USA, 104(7), 2050-55.
8. Cohen, F.J. (2005), 'Macro trends in pharmaceutical innovation', Nature Reviews in Drug Discovery, 4, 78-84.
9. Collier, T.L., R. Lecomte, J. McCarthy, T.J. Meikle, F. Scopinaro, A. Signore, H. VanBrocklin, C. Van de Wiele and R.N. Waterhouse (2002), 'Assessment of cancerassociated biomarkers by positron emission tomography: advances and challenges', Disease Markers, 18(5-6), 211-47.
10. Couvreur, P. and C. Vauthier (2006), 'Nanotechnology: intelligent design to treat complex disease', Pharmaceutical Research, 23(7), 1417-50.
11. De Jong, W.H. and P.J.A. Borm (2008), 'Drug delivery and nanoparticles: applications and hazards', International Journal of Nanomedicine, 3(2), 133-49.
12. Dobrovolskaia, M. and S. McNeil (2007), 'Immunological properties of engineered nanomaterials', Nature Nanotechnology, 2, 469-78.
13. Dobrovolskaia, M., P. Aggarwal, J.B. Hall and S.E. McNeil (2008a), 'Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution', Molecular Pharmaceutics, 5(4), 487-95.
14. Dobrovolskaia, M., J.D. Clogston, B.W. Neun, J.B. Hall, A.K. Patri and S.E. McNeil (2008b), 'Method for analysis of nanoparticle hemolytic properties', In Vitro Nano Letters, 8(8), 2180-87.
15. Dobrovolskaia, M., A.K. Patri, J. Zheng, J.D. Clogston, N. Ayub, P. Aggarwal, B.W. Neun, J.B. Hall and S.E. McNeil (2009a), 'Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles', Nanomedicine: Nanotechnology, Biology, and Medicine, 5, 106-17
16. Dobrovolskaia, M., D.R. Germolec and J.L. Weaver (2009b), 'Evaluation of nanoparticle immunotoxicity', Nature Nanotechnology, 4, 411-14.
17. Duncan, R. (2003a), 'The dawning era of polymer therapeutics', Nature Reviews in Drug Discovery, 2, 347-60.
18. Duncan, R. (2003b), 'Polymer-drug conjugates', in Daniel R. Budman, Alan H. Calvert, Eric K. Rowinsky (eds), Handbook of Anticancer Drug Development, Philadelphia, PA: Williams & Wilkins, pp. 239-60.
19. Duncan, R. (2009), 'Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt', Advanced Drug Delivery Reviews, 61, 1131-48.
20. Duncan, R., H. Ringsdorf and R. Satchi-Fainaro (2006), 'Polymer therapeutics - polymers as drugs, conjugates and gene delivery systems: past, present and future opportunities', Advances in Polymer Science, 192, 1-8.
21. Eaton, M. (2007), 'Nanomedicine: industry-wise research', Nature Materials, 6, 251-3.
22. Emerich, D.F. and C.G. Thanos (2008), 'Multifunctional peptide-based nanosystems for improving delivery and molecular imaging', Current Opinion Molecular Therapy, 10(2), 132-9.
23. European Group on Ethics in Science and New Technologies (2007), Opinion on the Ethical Aspects of Nanomedicine, Brussels: European Commission.
24. European Medicines Agency (EMA) (2006), Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Active Substance: Non-clinical and Clinical Issues, London: EMA.
25. European Medicines Agency (2007), Guideline on Requirements for First-in-man Clinical Trials for Potential High-risk Medicinal Products, London: EMA.
26. European Medicines Agency (2008), Final Report on the Pilot Joint EMA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers, London: EMA.
27. European Medicines Agency (2009), Qualification of Novel Methodologies for Drug Development: Guidance to Applicants, London: EMA.
28. European Science Foundation (ESF) (2005), Nanomedicine. An ESF-European Science Foundation, European Medical Research Councils (EMRC) Forward Look report, Brussels: ESF.
29. Fleischmann, R., J. Vencovsky, R. van Vollenhoven, D. Borenstein, J. Box, G. Coteur, N. Goel, H.-P. Brezinschek, A. Innes and V. Strand (2009), 'Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study', Annals of the Rheumatic Diseases, 68(6), 805-11.
30. Food and Drug Administration (FDA) (2002), Guidance for Industry: Liposome Drug Products, Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation, Washington, DC: FDA.
31. Food and Drug Administration - Critical Path Initiative (2004), Challenge and Opportunity on the Critical Path to New Medical Products, Washington, DC: FDA.
32. Garinot, M., V. Fiévez, V. Pourcelle, F. Stoffelbach, A. des Rieux, L. Plapied, I. Theate, H. Freichels, C. Jérôme, J. Marchand-Brynaert, Y.J. Schneider and V. Préat (2007), 'PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination', Journal of Controlled Release, 120(3), 195-204.
33. Gaspar, R. (2000), 'European drugs: Europe faces the future', Journal Pharmacie Belgique, 55(3), 69-73.
34. Gaspar, R. (2007), 'Regulatory issues surrounding nanomedicines: setting the scene for the next generation of nanopharmaceuticals', Nanomedicine, 2(2), 143-7.
35. Gaspar, R. (2009), 'The regulatory landscape: implications for design and development of nanomedicines', Journal of Pharmacy and Pharmacology, Suppl 1, A148-A149.
36. Gaspar, R. and R. Duncan (2009), 'Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics', Advanced Drug Delivery Reviews, 61, 1220-31.
37. Gauchel, G., B. Huppertz, H. Feiertag and R. Keller (2003), 'Clinical use of polyethylene glycols as marker substances and determination in urine by liquid chromatography', Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences, 787(2), 271-9.
38. Gaumet, M., A. Vargas, R. Gurny and F. Delie (2008), 'Nanoparticles for drug delivery: the need for precision in reporting particle size parameters', European Journal of Pharmaceutics and Biopharmaceutics, 69(1), 1-9.
39. Ghanem, G.E, C. Joubran, R. Arnould, F. Lejeune and J. Fruhling (1993), 'Labelled polycyanoacrylate nanoparticles for human in vivo use', Applied Radiation and Isotopes, 44(9), 1219-24.
40. Gradishar, W.J. (2006), 'Albumin-bound paclitaxel: a next-generation taxane', Expert Opinion on Pharmacotherapy, 7(8), 1041-53.
41. Hamad, I. and S.M. Moghimi (2008), 'Critical issues in site-specific targeting of solid tumours: the carrier, tumour barriers and the bioavailable drug', Expert Opinion Drug Delivery, 5(2), 205-19.
42. Hamad, I., A.C. Hunter, J. Szebeni and S.M. Moghimi (2008), 'Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process', Molecular Immunology, 46(2), 225-32.
43. Hardman, R. (2006), 'A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors', Environmental Health Perspectives, 114(2), 165-72.
44. Herndon, C.M. (2007), 'Iontophoretic drug delivery system: focus on fentanyl', Pharmacotherapy, 27(5), 745-54.
45. Hillaireau, H. and P. Couvreur (2009), 'Nanocarriers' entry into the cell: relevance to drug delivery', Cellular and Molecular Life Sciences, 66(17), 2873-96.
46. Ho, Y.-P. and K.W. Leong (2009), 'Quantum dot-based theranostics', Nanoscale, DOI: 10.1039/b9nr00178f.
47. Innovative Medicines Initiative (IMI) (2008), The Innovative Medicines Initiative Research Agenda: Creating Biomedical R&D Leadership for Europe to Benefit Patients and Society, Brussels: IMI.
48. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Q9 (ICH) (2005), Quality Risk Management. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Tripartite Guideline, Geneva: ICH.
49. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Q10 (2008), Pharmaceutical Quality System. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Tripartite Guideline, Geneva: ICH.
50. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Q8 (2009), Pharmaceutical Development. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Tripartite Guideline, Geneva: ICH.
51. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2009), ICH Topics Q8, Q9 and Q10 - Note for Guidance on Pharmaceutical Development/Quality Risk Management/Pharmaceutical Quality System (Questions and Answers), Geneva: ICH.
52. Jones, A. (2007), 'Minimizing leakage of value from R&D alliances', Nature Reviews in Drug Discovery, 6, 711-19.
53. Keystone, E., D. van der Heijde, D. Mason, R. Landewé, R. van Vollenhoven, B. Combe, P. Emery, V. Strand, P. Mease, C. Desai and K. Pavelka (2008), 'Certolizumab Pegol plus Methotrexate is significantly more effective than placebo plus Methotrexate in active rheumatoid arthritis', Arthritis & Rheumatism, 58(11), 3319-29.
54. Kim, W.J., C.W. Chang, M. Lee and S.W. Kim (2007), 'Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy', Journal of Controlled Release, 118(3), 357-63.
55. Kirchheiner, J., U. Fuhr and J. Brockmöller (2005), 'Pharmacogenetics-based therapeutic recommendations - ready for clinical practice?', Nature Reviews in Drug Discovery, 4, 639-47.
56. Kwong, G.A., C.G. Radu, K. Hwang, C.J. Shu, C. Ma, R.C. Koya, B. Comin-Anduix, S.R. Hadrup, R.C. Bailey, O.N. Witte, T.N. Schumacher, A. Ribas and J.R. Heath (2009), 'Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigenspecific T cells', Journal of American Chemical Society, 131(28), 9695-703.
57. Lee, E.S., Z. Gao and Y.H. Bae (2008), 'Recent progress in tumor pH targeting nanotechnology', Journal of Controlled Release, 132(3), 164-70.
58. Li, S.D. and L. Huang (2008), 'Pharmacokinetics and biodistribution of nanoparticles', Molecular Pharmaceutics, 5(4), 496-504.
59. Lu, J., E. Choi, F. Tamanoi and J.I. Zink (2008), 'Light-activated nanoimpeller-controlled drug release in cancer cells', Small, 4(4), 421-6.
60. Lundqvist, M., J. Stigler, G. Elia, I. Lynch, T. Cedervall and K.A. Dawson (2008), 'Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts', Proceedings National Academy Sciences USA, 105(38), 14265-70.
61. Maeda, H., G.Y. Bharate and J. Daruwalla (2009), 'Polymeric drugs for efficient tumortargeted drug delivery based on EPR-effect', European Journal of Pharmaceutics and Biopharmaceutics, 71(3), 409-19.
62. Matsumura, Y. and H. Maeda (1986), 'A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs', Cancer Research, 46(12), 6387-92.
63. McNeil, S.E. (2009), 'Nanoparticle therapeutics: a personal perspective', WIREs Nanomedicine and Nanobiotechnology, 1, 264-71.
64. Melnikova, I. (2009), 'Psoriasis market', Nature Reviews in Drug Discovery, 8(10), 767-8.
65. Minko, T., J.J. Khandare, A.A. Vetcher, V.A. Soldatenkov, O.B. Garbuzenko, M. Saad and V.P. Pozharov (2008), 'Multifunctional nanotherapeutics for cancer', in V. Torchilin (ed), Multifunctional Pharmaceutical Nanocarriers, New York: Springer Science, pp. 309-336.
66. Moen, M.D., K.A. Lyseng-Williamson and L.J. Scott (2009), 'Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections', Drugs, 69(3), 361-92.
67. Moghimi, S.M. and I. Hamad (2008), 'Liposome-mediated triggering of complement cascade', Journal of Liposome Research, 18(3), 195-209.
68. Moghimi, S.M. and T.L. Andresen (2009), 'Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines', Molecular Immunology, 46(8-9), 1571-2.
69. Mohamed, F. and C.F. van der Walle (2008), 'Engineering biodegradable polyester particles with specific drug targeting and drug release properties', Journal of Pharmaceutical Sciences, 97(1), 71-87.
70. Moinard-Checot, D., Y. Chevalier, S. Briançon, H. Fessi and S. Guinebretière (2006), 'Nanoparticles for drug delivery: review of the formulation and process difficulties illustrated by the emulsion-diffusion process', Journal of Nanoscience and Nanotechnology, 6(9-10), 2664-81.
71. Morais, P.C. (2009), 'Photoacoustic spectroscopy as a key technique in the investigation of nanosized magnetic particles for drug delivery systems', Journal of Alloys and Compounds, 483(1-2), 544-8.
72. Mrózek, E., C.A. Rhoades, J. Allen, E.M. Hade and C.L. Shapiro (2005), 'Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients', Annals of Oncology, 16(7), 1087-93.
73. Mundargi, R.C., V.R. Babu, V. Rangaswamy, P. Patel and T.M. Aminabhavi (2008), 'Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-coglycolide) and its derivatives', Journal of Controlled Release, 125, 193-209.
74. National Institute for Health and Clinical Excellence (NICE) (2002), A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer, technology assessment report, Washington, DC: NICE.
75. Nel, A.E., L. Mädler, D. Velegol, T. Xia, E.M. Hoek, P. Somasundaran, F. Klaessig, V. Castranova and M. Thompson (2009), 'Understanding biophysicochemical interactions at the nano-bio interface', Nature Materials, 8(7), 543-57.
76. Nicolas, J. and P. Couvreur (2009), 'Synthesis of poly(alkyl cyanoacrylate)- based colloidal nanomedicines', WIREs Nanomedicine and Nanobiotechnology, 1(1), 111-27.
77. Nijhara, R. and K. Balakrishnan (2006), 'Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties', Nanomedicine: Nanotechnology, Biology and Medicine, 2(2), 127-36.
78. Oliver, M., A. Ahmad, N. Kamaly, E. Perouzel, A. Caussin, M. Keller, A. Herlihy, J. Bell, A.D. Miller and M.R. Jorgensen (2006), 'MAGfect: a novel liposome formulation for MRI labelling and visualization of cells', Organic and Biomolecular Chemistry, 4(18), 3489-97.
79. Omidi, Y. and J. Barar (2009), 'Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures', International Journal of Toxicology, 28(2), 113-22.
80. Park, Y.J., J.Y. Lee, Y.S. Chang, J.M. Jeong, J.K. Chung, M.C. Lee, K.B Park and S.J. Lee (2002), 'Radioisotope carrying polyethylene oxide-polycaprolactone copolymer micelles for targetable bone imaging', Biomaterials, 23(3), 873-9.
81. Patel, H.M., K.M. Boodle and R. Vaughan-Jones (1984), 'Assessment of the potential uses of liposomes for lymphoscintigraphy and lymphatic drug delivery. Failure of 99m-technetium marker to represent intact liposomes in lymph nodes', Biochimica Biophysica Acta, 801(1), 6-86.
82. Peer, D., J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit and R. Langer (2007), 'Nanocarriers as an emerging platform for cancer therapy', Nature Nanotechnology, 2, 751-60.
83. Pereira, M.A., V.C. Mosqueira, J.M. Vilela, M.S. Andrade, G.A. Ramaldes and V.N. Cardoso (2008), 'PLA-PEG nanocapsules radiolabelled with 99m Technetium-HMPAO: release properties and physico-chemical characterization by atomic force microscopy and photon correlation spectroscopy', European Journal Pharmaceutical Sciences, 33(1), 42-51.
84. Petre, C.E. and D.P. Dittmer (2007), 'Liposomal daunorubicin as treatment for Kaposi's sarcoma', International Journal of Nanomedicine, 2(3), 277-88.
85. Pharma 2020 (2009), Pharma 2020: Challenging Business Models - Which Path Will You Take?, London: PriceWaterhouseCoopers.
86. Pharmaceutical Inspection Cooperation Scheme (2007), Recommendation on Quality System Requirements for Pharmaceutical Inspectorates, Geneva: PIC/S.
87. Phillips, W.T., A.S. Rudolph, B. Goins, J.H. Timmons, R. Klipper and R. Blumhardt (1992), 'A simple method for producing a technetium-99m-labelled liposome which is stable in vivo', International Journal of Radiation Applications and Instrumentation - Part B, 19(5), 539-47.
88. Pillai, S., A.G. Hemmersam, R. Mukhopadhyay, R.L. Meyer, S.M. Moghimi, F. Besenbacher and P. Kingshott (2009), 'Tunable 3D and 2D polystyrene nanoparticle assemblies using surface wettability, low volume fraction and surfactant effects', Nanotechnology, 20(2), 25604.
89. Plosker, G.L. (2008), 'Pegylated liposomal doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma', Drugs, 68(17), 2535-51.
90. Pricl, S., M. Fermeglia and A. Asquini (2003), 'Scaling properties in the molecular structure of three-dimensional, nanosized phenylene-based dendrimers as studied by atomistic molecular dynamics simulations', Carbon, 41(12), 2269-83.
91. Qin, L., O. Vermesh, Q. Shi and J.R. Heath (2009), 'Self-powered microfluidic chips for multiplexed protein assays from whole blood', Lab Chip, 9(14), 2016-20.
92. Rademaker-Lakhai, J.M., C. Terret, S.B. Howell, C.M. Baud, R.F. de Boer, D. Pluim, J.H. Beijnen, J.H.M. Schellens and J.P. Droz (2004), 'A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors', Clinical Cancer Research, 10, 3386-95.
93. Rihova, B. (1996), 'Biocompatibility of biomaterials: haematocompatibility, immunocompatibility, and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers', Advanced Drug Delivery Reviews, 21, 157-76.
94. Rihova, B. and I. Riha (1984), 'Immunological problems of polymer-bound drugs', CRC Critical Reviews in Therapeutic Drug Carrier Systems, 1, 311-74.
95. Schipper, M.L., N. Nakayama-Ratchford, C.R. Davis, N.W. Kam, P. Chu, Z. Liu, X. Sun, H. Dai and S.S. Gambhir (2008), 'A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice', Nature Nanotechnology, 3(4), 216-21.
96. Schoemaker, N.E., C. van Kesteren, H. Rosing, S. Jansen, M. Swart, J. Lieverst, D. Fraier, M. Breda, C. Pellizzoni, R. Spinelli, M. Grazia Porro, J.H. Beijnen, J.H.M. Schellens and W.W. ten Bokkel Huinink (2002), 'A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin', British Journal of Cancer, 87, 608-14.
97. Seymour, L., D.R. Ferry, D. Anderson, S. Hesslewood, P.J. Julyan, R. Poyner, J. Doran, A.M. Young, S. Burtles and D.J. Kerr (2002), 'Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin', Journal of Clinical Oncology, 20(6), 1668-76.
98. Seymour, L.W., D.R. Ferry, D.J. Kerr, D. Rea, M. Whitlock, R. Poyner, C. Boivin, S. Hesslewood, C. Twelves, R. Blackie, A. Schatzlein, D. Jodrell, D. Bissett, H. Calvert, M. Lind, A. Robbins, S. Burtles, R. Duncan and J. Cassidy (2009), 'Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer', International Journal of Oncology, 34(6), 1629-36.
99. Shenoy, D., S. Little, R. Langer and M. Amiji (2005), 'Poly(ethylene oxide)- modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies', Pharmaceutical Research, 22(12), 2107-14.
100. Shmeeda, H., D. Tzemach, L. Mak and A. Gabizon (2009), 'Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage', Journal of Controlled Release, 136(2), 155-60.
101. Singer, J.W. (2005), 'Paclitaxel poliglumex (XYOTAX™, CT-2103) a macromolecular taxane', Journal of Controlled Release, 109(1-3), 120-26.
102. Smolen, J.S., R.B.M. Landewé, P.J. Mease, J. Brzezicki, D. Mason, K. Luijtens, K. van Vollenhoven, A. Kavanaugh, M.H. Schiff, G.R. Burmester, V. Strand, J. Vencovsky and D.M.F.M. van der Heijde (2009), 'Efficacy and safety of Certulizumab Pegol plus Methotrexate in active rheumatoid arthritis: the RAPID2 study', Annals of Rheumatic Diseases, 68(6), 797-804.
103. Szebeni, J. and S.M. Moghimi (2009), 'Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions', Journal of Liposome Research, 19(2), 85-90.
104. Torchilin, V. (2006), 'Multifunctional nanocarriers', Advanced Drug Delivery Reviews, 58(14), 1532-55.
105. Torchilin, V. (2009), 'Multifunctional and stimuli-sensitive pharmaceutical nanocarriers', European Journal of Pharmaceutics and Biopharmaceutics, 71(3), 431-44.
106. Udhrain, A., K.M. Skubitz and D.W. Northfelt (2007), 'Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma', International Journal of Nanomedicine, 2(3), 345-52.
107. Uversky, V.N., A.V. Kabanov and Y.L. Lyubchenko (2006), 'Nanotools for megaproblems: probing protein misfolding diseases using nanomedicine modus operandi', Journal of Proteome Research, 5(10), 2505-22.
108. Vasey, P.A., S.B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A.H. Thomson, L.S. Murray, T.E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio and J. Cassidy (1999), 'Phase I clinical and pharmacokinetic study of PK1 [N-(2-Hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutics', Clinical Cancer Research, 5, 83-94.
109. Wagner, E. (2007), 'Programmed drug delivery: nanosystems for tumor targeting', Expert Opinion in Biology and Therapeutics, 7(5), 587-93.
110. Watchers, F.M., H.J.M. Groen, J.G. Maring, J.A. Gietema, M. Porro, H. Dumez, E.G.E. de Vries and A.T. van Oosterom (2004), 'A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumors', British Journal of Cancer, 90, 2261-7.
111. Weiss, B., U.F. Schaefer, J. Zapp, A. Lamprecht, A. Stallmach and C.M. Lehr (2006), 'Nanoparticles made of fluorescence-labelled Poly(L-lactide-co-glycolide): preparation, stability and biocompatibility', Journal of Nanosciences and Nanotechnology, 6(9-10), 3048-56.
112. Welz, C., W. Neuhuber, H. Schreier, M. Metzler, R. Repp, W. Rascher and A. Fahr (2000), 'Nuclear transport of oligonucleotides in HepG2-cells mediated by protamine sulfate and negatively charged liposomes', Pharmaceutical Research, 17(10), 1206-11.
113. Wise, L., J. Parkinson, J. Raine and A. Breckenridge (2009), 'New approaches to drug safety: a pharmacovigilance tool kit', Nature Reviews in Drug Discovery, 8(10), 779-82.
114. Zhou, R., R.V. Mazurchuk, J.H. Tamburlin, J.M. Harrold, D.E. Mager and R.M. Straubinger (2009), 'Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model', Journal of Pharmacology and Experimental Therapeutics, 332(2), 479-88.
115. Zhou, Z.H. (2008), 'Towards atomic resolution structural determination by single-particle cryo-electron microscopy', Current Opinion Structural Biology, 18(2), 218-28.
116. Zolnik, B.S. and N. Sadrieh (2009), 'Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs', Advanced Drug Delivery Reviews, 61(6), 422-7.